[Effect of dauricine on redistribution of glycoprotein IV in platelet membrane of patients with mitral stenosis].
OBJECTIVE
To investigate the effect of dauricine on the irreversible platelet aggregability of patients with mitral stenosis (MS).


METHODS
Glycoprotein IV (GP IV) and thrombospondin (TSP) levels on the membrane surface of the stationary platelet or platelet activated by thrombin (0.05 U/ml, 0.1 U/ml, 0.5 U/ml, 1.0 U/ml) in 16 patients with MS were measured with flow cytometric method and compared with those of the healthy (14 cases).


RESULTS
The GP IV level of stationary platelet, the GP IV and TSP levels of activated platelet in MS patients were higher than those in the healthy significantly (P < 0.01), while the TSP level of stationary platelet was not different between the patients and the healthy (P > 0.05). The GP IV redistribution on the activated platelet surface was apparently inhibited by dauricine (50 mumol/L, P < 0.05, P < 0.01) and the release of TSP from intracellular alpha-granules was inhibited by dauricine only in the activated platelets induced by thrombin of low concentration (0.05 U/ml and 0.1 U/ml, P < 0.05, P < 0.01), inhibiting effect was not found in those activated with high concentration of thrombin.


CONCLUSIONS
The activity and reactivity to thrombin of platelets increased in MS patients, and dauricine was able to reduce the occurrence of the irreversible platelet aggregation in MS patients.
Zhang
Y
Y
Dept. of Cardiology, Institute of Cardiovascular Disease, Tongji Medical University, Wuhan 430022.
Liu
D
D
Li
Y
Y
D000328:Adult; D000470:Alkaloids; D044182:Benzylisoquinolines; D001792:Blood Platelets / Q000378:metabolism; D018955:CD36 Antigens / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008946:Mitral Valve Stenosis / Q000097:blood / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D044005:Tetrahydroisoquinolines; D019699:Thrombospondins / Q000378:metabolism
D000470:Alkaloids; D044182:Benzylisoquinolines; D018955:CD36 Antigens; D007546:Isoquinolines; D010975:Platelet Aggregation Inhibitors; D044005:Tetrahydroisoquinolines; D019699:Thrombospondins; C035934:dauricine